FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

연구 용도로만 사용. 전체 공지 →

연구/Exploring the Metabolic Pathways of Alexamorelin: Challenges in Detecting Its Use
연구 도서관으로 돌아가기
AlexamorelinExamorelinHexarelin

Exploring the Metabolic Pathways of Alexamorelin: Challenges in Detecting Its Use

May 16, 2026
Share

원본 논문

Identification of alexamorelin consumption biomarkers using human hepatocyte incubations and high-resolution mass spectrometry.

Pobee Elizabeth et al.Journal of analytical toxicology2025
Emergent 연구

이 주제에 대한 잠재적인 결과가 있지만 추가 검증이 필요합니다. 이러한 발견은 유망하지만 확실하지 않습니다.

이 분석에 대해 알아보기

이 기사는 위의 원본 논문에서 발견한 결과를 피테이드 연구 커뮤니티에게 이해하기 쉬운 언어로 분해합니다. 우리의 목표는 가장 중요한 사항을 강조하는 것입니다 — 실용적 의미, 증거의 강도, 그리고 현재 진행 중인 연구에 대한 의미.

Unraveling Alexamorelin's Metabolic Pathways: New Insights but Challenges Persist

Published: May 16, 2026 | Source: Journal of analytical toxicology (2025) | Category: Alexamorelin, Examorelin, Hexarelin

Overview

A recent study published in the Journal of Analytical Toxicology has shed light on the metabolic pathways of alexamorelin, a synthetic peptide with growth hormone secretagogue properties. The research highlights the complexity of detecting this substance's use due to its rapid metabolism and transformation into other peptides like examorelin (hexarelin), which complicates efforts in doping control.

Study Background

Alexamorelin is a performance-enhancing drug that mimics natural hormones to boost growth hormone levels, making it a target for anti-doping regulations. However, identifying biomarkers of its consumption has been challenging due to the rapid and extensive metabolism by the liver. This study aimed to predict and characterize these metabolic pathways using computational tools and in vitro human hepatocyte models.

What the Research Found

The research team used GLORYx software to predict 21 potential metabolites of alexamorelin, with N-acetylation at either the C-terminal alanine or N-terminal lysine being the most likely transformation. After incubating alexamorelin with pooled human hepatocytes for three hours, only one specific metabolite was detected: examorelin (hexarelin), which results from cleavage of the C-terminal alanine residue.

What This Means for Peptide Users

The findings suggest that detecting alexamorelin's use may be more challenging than previously thought due to its rapid transformation into other peptides. Examorelin, a known growth hormone secretagogue, is not specific to alexamorelin consumption, complicating efforts in identifying the exact substance used by athletes or patients.

Limitations and Caveats

The study’s reliance on computational predictions and in vitro hepatocyte models limits its applicability to real-world scenarios involving human subjects. Additionally, the detection of examorelin rather than unique metabolites specific to alexamorelin poses significant challenges for doping control measures.

How This Compares to Previous Research

Previous studies have focused on identifying biomarkers through urine or blood samples from athletes and patients, but this study’s approach provides a more detailed understanding of the metabolic pathways involved. However, it also highlights the need for further research using human subjects to validate these findings in practical settings.

Our Analysis

PeptideVault's analysis suggests that while this study advances our knowledge of alexamorelin metabolism, its limitations underscore the complexity of detecting such substances accurately. The identification of examorelin as a primary metabolite raises questions about the specificity and reliability of current detection methods for performance-enhancing peptides like alexamorelin.

Key Takeaways

  • Complex Metabolism: Alexamorelin undergoes rapid metabolism, primarily through N-acetylation.
  • Challenges in Detection: The transformation into examorelin complicates efforts to detect alexamorelin specifically.
  • Need for Further Research: Studies using human subjects are necessary to validate these findings and improve detection methods.

Original Source

Citation: Pobee Elizabeth, Daziani Gloria, Gameli Prince S et al. (2025). Identification of alexamorelin consumption biomarkers using human hepatocyte incubations and high-resolution mass spectrometry.. Journal of analytical toxicology. DOI: 10.1093/jat/bkaf038

Access:

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

편집자의 주석

이 분석은 Peptide Contacts 연구 팀에 의해 작성되었습니다. 항상 원문을 참조하고 자격 있는 의료 전문가와 상담하기 위해 원본 논문 전체 방법론 및 데이터는 여기에서 확인하실 수 있습니다. 원래 출판물은 {source}에서 확인하실 수 있습니다. PubMed.

관련 연구

Comments

Sign in to join the discussion

이 분석은 교차 검토된 연구를 기반으로 교육 목적용으로 생성되었습니다. 이 내용은 의학적 조언으로 간주되지 않습니다. 피테이드 기반 치료법을 사용하기 전에 항상 자격 있는 의료 전문가와 상담하십시오.